Straits Times Index
3,319.43 +11.53 (+0.35%) Nikkei
39,103.22 +486.12 (+1.26%) Hang Seng
18,865.69 -329.91 (-1.72%) FTSE 100
8,358.26 -12.07 (-0.14%) Bitcoin USD
69,745.66 -19.35 (-0.03%) CMC Crypto 200
1,514.20 +11.53 (+0.77%)
Basilea Pharmaceutica AG (BSLN.SW)
| Previous close | 43.25 |
| Open | 43.00 |
| Bid | 43.60 x 0 |
| Ask | 43.80 x 0 |
| Day's range | 42.90 - 43.75 |
| 52-week range | 32.00 - 49.00 |
| Volume | |
| Avg. volume | 33,969 |
| Market cap | 525.14M |
| Beta (5Y monthly) | 0.56 |
| PE ratio (TTM) | 50.87 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 11 Apr 2013 |
| 1y target est | N/A |
- GlobeNewswire
Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea
Allschwil, Switzerland, May 16, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that the continued strong sales performance of the antifungal Cresemba® (isavuconazole) by its license partner Pfizer Inc. in the Asia Pacific region and China exceeded the sales threshold triggering a USD 1.25 million milestone payment. David Veitch, Basilea’s Ch
- GlobeNewswire
Basilea reports presentation of new data for ceftobiprole (Zevtera®) at ESCMID Global 2024
Allschwil, Switzerland, May 03, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that scientific presentations with new data on its antibiotic ceftobiprole (Zevtera®) have been presented at ESCMID Global 2024, the annual meeting of the European Society of Clinical Microbiology and Infectious Diseases, which took place from April 27 to 30, 2024
- GlobeNewswire
Basilea shareholders approve all proposals of the board of directors at the annual general meeting
Allschwil, Switzerland, April 24, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, reported that shareholders approved all proposals of the board of directors at today’s annual general meeting (AGM) for the financial year 2023. At the AGM, the shareholders approved the annual report, the financial statements and the consolidated financial statements for the f
